Organogenesis Holdings (ORGO) Price & Analysis

Compare

469 Followers

ORGO Stock Chart & Stats

$4.06

-$0.06(-1.89%)

At close: Jan 08 4:00 PM EST

$4.06

-$0.06(-1.89%)

Day’s Range― - ―

52-Week Range$2.61 - $6.71

Previous CloseN/A

Volume97.61K

Average Volume (3M)785.65K

Market Cap

$515.04M

Enterprise Value$559.34M

Total Cash (Recent Filing)$73.08M

Total Debt (Recent Filing)$40.82M

Price to Earnings (P/E)928.6

Beta1.66

Next Earnings

Nov 06, 2025

EPS Estimate

0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding126,857,710

10 Day Avg. Volume515,226

30 Day Avg. Volume785,649

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.09

Enterprise Value/Revenue1.30

Enterprise Value/Gross Profit1.78

Enterprise Value/Ebitda-40.00

Forecast

1Y Price Target

$6.67

Price Target Upside64.29% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationDespite the second trial's results, the analyst's recommendation for ORGO remains a Buy.

ValuationORGO's valuation is seen as favorable risk/reward, suggesting potential for share price increase.

Bears Say

Revenue MissRevenue of $101.0M missed estimates due to LCD dynamics and changes to CMS' proposals impacting results.

Trial ResultsThe second Phase 3 trial did not achieve statistical significance for its primary endpoint, as the control group had better-than-expected improvements in pain.

Organogenesis Holdings News

Organogenesis provides update on second Phase 3 ReNu study

Organogenesis (ORGO) announced that the second Phase 3 randomized controlled trial of ReNu, a cryopreserved amniotic suspension allograft...

23d ago

ORGO

Buy Rating for Organogenesis Holdings Despite Mixed Trial Results, Supported by Diversified Revenue and FDA Clearance Efforts

BTIG analyst Ryan Zimmerman maintained a Buy rating on Organogenesis Holdings yesterday and set a price target of...

22d ago

ORGO

Organogenesis Holdings Faces Setback in ReNu Phase 3 Trial

Organogenesis Holdings ( ($ORGO) ) has issued an announcement. On September 25, 2025, Organogenesis Holdings announced that its...

23d ago

ORGO

Buy Rating for Organogenesis Holdings Amid Favorable Medicare Pricing and Market Positioning

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Organogenesis Holdings, with a...

1M ago

ORGO

Organogenesis Holdings’ Earnings Call: Mixed Sentiments and Strategic Moves

Organogenesis Holdings (($ORGO)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

ORGO

Organogenesis Holdings Reports Mixed Q2 2025 Results

Organogenesis Holdings ( ($ORGO) ) has released its Q2 earnings. Here is a breakdown of the information Organogenesis...

2M ago

ORGO

Organogenesis Amends Credit Agreement Amid Revenue Decline

An update from Organogenesis Holdings ( ($ORGO) ) is now available. On August 5, 2025, Organogenesis Holdings Inc....

2M ago

ORGO

MiMedx price target raised to $12 from $11 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on MiMedx (MDXG) to $12 from $11 and keeps an Overweight...

3M ago

MDXG

ORGO

Video: Why Organogenesis And MiMedx Are Sinking Today

The Fly has brought its to-the-moment stock market reporting to YouTube! Listen and subscribe. Published first on TheFly...

3M ago

MDXG

ORGO

Organogenesis ‘pleased’ with CMS proposal on skin substitute

Organogenesis (ORGO) said it “applauds” the Centers for Medicare and Medicaid Services’ proposed new payment approach for skin...

3M ago

ORGO

Organogenesis applauds CMS for proposed new payment for CTPs

Organogenesis (ORGO) applauds the Centers for Medicare & Medicaid Services’, CMS, proposed new payment approach for skin substitutes/cellular...

3M ago

ORGO

Organogenesis selloff on CMS proposal ‘may be incorrect,’ says BTIG

BTIG believes the selloff in shares of Organogenesis (ORGO) on the Centers for Medicare and Medicaid Services’ proposed...

3M ago

MDXG

ORGO

Organogenesis, MiMedx fall after CMS rule to cut skin substitutes spending

The Centers for Medicare and Medicaid Services announced a proposed rule “that would increase quality care for Medicare...

3M ago

MDXG

ORGO

Organogenesis Holdings Approves Key Proposals at Annual Meeting

The latest update is out from Organogenesis Holdings ( ($ORGO) ). On June 23, 2025, Organogenesis Holdings held...

4M ago

ORGO

ORGO FAQ

What was Organogenesis Holdings Inc’s price range in the past 12 months?

Organogenesis Holdings Inc lowest stock price was $2.61 and its highest was $6.71 in the past 12 months.

What is Organogenesis Holdings Inc’s market cap?

Organogenesis Holdings Inc’s market cap is $515.04M.

When is Organogenesis Holdings Inc’s upcoming earnings report date?

Organogenesis Holdings Inc’s upcoming earnings report date is Nov 06, 2025 which is in 19 days.

How were Organogenesis Holdings Inc’s earnings last quarter?

Organogenesis Holdings Inc released its earnings results on Aug 07, 2025. The company reported -$0.063 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.013.

Is Organogenesis Holdings Inc overvalued?

According to Wall Street analysts Organogenesis Holdings Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Organogenesis Holdings Inc pay dividends?

Organogenesis Holdings Inc does not currently pay dividends.

What is Organogenesis Holdings Inc’s EPS estimate?

Organogenesis Holdings Inc’s EPS estimate is 0.07.

How many shares outstanding does Organogenesis Holdings Inc have?

Organogenesis Holdings Inc has 126,857,710 shares outstanding.

What happened to Organogenesis Holdings Inc’s price movement after its last earnings report?

Organogenesis Holdings Inc reported an EPS of -$0.063 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went up 0.885%.

Which hedge fund is a major shareholder of Organogenesis Holdings Inc?

Currently, no hedge funds are holding shares in ORGO

Organogenesis Holdings Stock Smart Score

Outperform

Fundamentals

Return on Equity

-2.64%

Trailing 12-Months

Asset Growth

4.05%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Organogenesis Holdings Inc

Organogenesis Holdings Inc. is a leader in regenerative medicine, specializing in the development and commercialization of innovative advanced wound care and surgical biologics. The company operates primarily in the healthcare sector, focusing on products that utilize human cellular and tissue-based therapies. Its core offerings include dermal regeneration matrices, skin substitutes, and other advanced wound care solutions aimed at improving patient outcomes in chronic and complex wounds.

Organogenesis Holdings (ORGO) Earnings & Revenues

Historic Earnings Reports

ORGO Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed outlook. While there are positive developments such as growth in the Surgical & Sports Medicine segment, proposed CMS payment reforms, and progress in the ReNu program, the company faced significant challenges with a decline in Advanced Wound Care revenue, overall revenue decrease, and reduced financial guidance.View all ORGO earnings summaries

ORGO Stock 12 Month Forecast

Average Price Target

$6.67

▲(64.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","10":"$10","3.25":"$3.25","5.5":"$5.5","7.75":"$7.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.25,5.5,7.75,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.9,5.2153846153846155,5.530769230769231,5.846153846153847,6.161538461538462,6.476923076923077,6.792307692307693,7.107692307692308,7.423076923076923,7.7384615384615385,8.053846153846154,8.36923076923077,8.684615384615384,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.9,5.036153846153846,5.172307692307693,5.308461538461539,5.444615384615385,5.580769230769231,5.716923076923077,5.853076923076923,5.989230769230769,6.125384615384616,6.2615384615384615,6.397692307692308,6.533846153846154,{"y":6.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.9,4.830769230769231,4.7615384615384615,4.6923076923076925,4.6230769230769235,4.553846153846154,4.484615384615385,4.415384615384616,4.346153846153847,4.276923076923077,4.207692307692308,4.138461538461538,4.069230769230769,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.75,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.68,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >